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Abstract
Immune interferon (IFN), also known as IFN-γ, promotes not only immunomodulation but also antimicrobial and
anticancer activity. After IFN-γ binds to the complex of IFN-γ receptor (IFNGR) 1-IFNGR2 and subsequently activates
its downstream signaling pathways, IFN-γ immediately causes transcriptional stimulation of a variety of genes that
are principally involved in its biological activities. Regarding IFN-γ-dependent immunosurveillance, IFN-γ can directly
suppress tumorigenesis and infection and/or can modulate the immunological status in both cancer cells and infected
cells. Regarding the anticancer effects of IFN-γ, cancer cells develop strategies to escape from IFN-γ-dependent
cancer immunosurveillance. Immune evasion, including the recruitment of immunosuppressive cells, secretion of
immunosuppressive factors, and suppression of cytotoxic T lymphocyte responses, is speculated to be elicited by the
oncogenic microenvironment. All of these events effectively downregulate IFN-γ-expressing cells and IFN-γ production.
In addition to these extrinsic pathways, cancer cells may develop cellular tolerance that manifests as hyporesponsiveness
to IFN-γ stimulation. This review discusses the potential escape mechanisms from IFN-γ-dependent immunosurveillance
in tumorigenesis.
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Background
Tumorigenesis is a complicated pathogenesis character-
ized by the hallmarks of cancer development such as [1]
causing instability and mutation in genome, [2] resisting
cell death response, [3] deregulating the requirement of
cellular energetics, [4] sustaining proliferative signaling
pathways, [5] evading growth suppressor response, [6]
avoiding immune recognition and destruction, [7] enab-
ling replicative immortality ability, [8] facilitating tumor-
promoting microenvironment, [9] activating invasion
and metastasis processes, and [10] inducing angiogenic
status. Regarding malignancies that are derived from im-
mortalized and transformed cells whose genomes have
become altered or mutated, a variety of oncogenic alter-
ations (including activation of the PI3K/AKT and Ras/
Raf/MEK/ERK pathways as well as growth factor recep-
tors) and either the inactivation or decreased expression
of tumor suppressors such as p53, adenomatous polyp-
osis coli mutations, phosphatase and tensin homolog
deleted on chromosome 10 (PTEN), and runt-related
transcription factor 3 are pathologically contributed to
tumor growth and survival [33]. For immune-based
anticancer defense, the immunosurveillance processes of
elimination act as tumor-killing defenders; however,
through immunoediting, cancer cells initially trigger tol-
erance, senescence, and/or equilibrium with the immune
system followed by the induction of immune escape to
promote malignant carcinogenesis [21, 22]. The early
stages of most cancers are asymptomatic; however,
cancer cells are proliferated and then invaded into the
lymph nodes and nearby organs leading to mortality. For
immune evasion, tumors develop a number of escape
strategies from host surveillance [3, 50]. Despite cooper-
ating with tumor-infiltrating immune cells harboring the
immunosuppressive activities such as tumor-associated
macrophages (TAMs), cluster of differentiation (CD) 4+
CD25+ forkhead box P3 (FOXP3)+ regulatory T cells
(Treg), and myeloid-derived suppressor cells (MDSCs)
[7], it is unclear whether oncogenic processes are also
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involved in the immune escape of cancer cells by indu-
cing a cellular immune tolerance in response to immune
recognition and activation.
Cancer immunosurveillance
Through the immune system, immunosurveillance con-
fers specific and immediate recognition not only of
pathogen-infected cells but also of healthy cells that have
been immortalized and/or transformed during tumori-
genesis [44]. As is known, a variety of cancerous events,
such as chemical and infectious carcinogens, hazardous
radicals, and carcinogenetic alterations, cause tumori-
genesis by altering the expression and/or activation of
oncogenes as well as the inactivation of tumor suppres-
sor genes [33]. Under immunosurveillance, immune cells
such as T cells, natural killer (NK) cells, NKT cells, γδ T
cells, and macrophages functionally translocate into
tumor sites and trigger anticancer immunity by secreting
several cytotoxic molecules including interferon (IFN)-γ,
tumor necrosis factor (TNF)-α, perforin, granzyme,
CD95 ligand (FasL), and TNF-related apoptosis-inducing
ligand (TRAIL) [21, 22, 69]. An increased cytotoxic T
lymphocyte (CTL) response confers better survival
against cancers, while the suppression of CTLs increases
the susceptibility of the host to carcinogenesis, indicat-
ing a major anticancer immunity due to CTLs [31].
Concurrently, infiltrated NK, NKT, and γδ T cells also
display anticancer immunity [24, 32, 44, 69].
After cell-cell contact recognition, most anticancer-
related cytotoxic and immune modulatory factors
secreted from CTLs, NK/NKT cells, and γδ T cells can
target cancer cells to directly induce cancer cell apop-
tosis and/or to sensitize the cancer cell response to
apoptotic stimuli. Through a perforin-delivered intracel-
lular granzyme B system, cancer cells can be disrupted
by granzyme B-mediated cellular toxicity via different
pathways, which subsequently results in cancer cell
damage toward immunological cell death [51, 68]. In
addition to cytolytic perforin and granzyme B, death
ligands such as the CD95 ligand and TRAIL, which are
mainly secreted from activated CTLs and NK cells, also
influence anticancer immunity [41, 51, 72]. Upon activa-
tion of CLTs and NK cells, the CD95 ligand and TRAIL
are de novo synthesized and either expressed on the sur-
face of CTLs and NK cells or released via an exosome-
mediated pathway to kill susceptible tumor cells through
the interaction of these ligands with their respective
death receptors. Cancer immunosurveillance allows for
the elimination of immortalized and transformed cells
from cancerous regions.
IFN-γ-dependent cancer immunosurveillance
Either type I IFN-α/-β or type II immune IFN-γ are potent
cytokines that are cytoprotective against tumorigenesis
[57]. Similar to perforin-deficient mice, IFN-γ-deficient
mice spontaneously develop lung epithelial malignancies
and lymphoma [66], confirming the anticancer ability of
IFN-γ. Similarly, IFN-γ receptors (IFNGRs)- and signal
transducer and activator of transcription (STAT) 1-
deficient mice advance tumor growth after chemical
carcinogen treatment. Furthermore, exogenous adminis-
tration of IFN-γ is used for treating patients with ovarian
cancer, adult T cell leukemia and malignant melanoma
[53]. Decreased levels of IFN-γ and/or the generation of
genetic defects in IFN-γ signaling factors, including single
nucleotide polymorphisms in IFN-γ, IFN-regulating fac-
tors (IRFs), and its receptor IFNGR2, are risk factors for
tumorigenesis in humans [70]. In addition to cytotoxic
factors, IFN-γ secreted from CTLs, NK cells, NKT cells,
and γδ T cells acts as a potent anticancer cytokine
[54, 69]. IFN-γ exhibits a variety of important biological
activities: not only does IFN-γ confer antimicrobial and
immunomodulatory effects—inducing MHC-mediated
antigen presentation pathways, developing type 1 T helper
cell (Th1) responses, causing anti-microbe effects, regulat-
ing leukocyte trafficking, and facilitating Toll-like receptor
signaling—but it also promotes anticancer activities [65].
IFN-γ binds IFNGR1 and IFNGR2, which are associated
with Janus kinase (JAK) 1 and JAK2, respectively. Acti-
vated JAKs cause tyrosine phosphorylation of STAT1
followed by the formation of STAT1-STAT1 homodimers.
In addition to JAKs, IFN-γ causes p38 mitogen-activated
protein kinase (MAPK) activation to mediate the phos-
phorylation of Ser727 on both STAT1 and STAT3 [46].
After activation, STATs translocate into the nucleus and
bind to IFN-γ-activated site (GAS) elements for initiating
the transcription of several genes related to anticancer
such as major histocompatibility complex (MHC) class I,
CD95 (Fas), caspase-1 and other genes associated with
growth inhibition [60].
IFN-γ displays anticancer activity by attenuating can-
cer cell growth. After IFN-γ stimulation, p21 and p27
are expressed to arrest the cell cycle by attenuating the
stability of cyclin/cyclin-dependent kinase complexes
[34, 45]. In addition, IFN-γ increases the expression of
miRNAs to contribute to p53-regulated cell cycle arrest
[49, 63]. Through a direct effect, IFN-γ induces cell
apoptosis via Bcl-2 downregulation [84]. The activation
of cathepsin, generation of reactive oxygen species
(ROS), and induction of endoplasmic reticulum (ER)
stress are involved in the apoptotic signaling of IFN-γ
[86]. Exogenous administration of IFN-γ causes a mimic
extracellular trap cell death (ETosis) in A549 adenocar-
cinoma cells [47, 48]. In IFN-γ-treated lung epithelial
malignancies, IFN-γ induces autophagy in IFN-inducible
immunity-related p47 GTPase IRGM1- and activating
transcription factor 6-regulated manners. The induced
autophagosome may serve as a platform for Atg5/Fas-
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associated protein with death domain-mediated caspase-
8/caspase-3 activation, while IFN-γ induces IRF-1-
mediated caspase cascade activation. Caspase-mediated
lamin A/C degradation causes DNA damage followed by
ataxia telangiectasia mutated (ATM) and ATR (ATM
and Rad3-related) activation and γ-H2AX phosphoryl-
ation. Through an unknown mechanism, ATR/ATM
regulates protein arginine deiminase (PAD) 4-mediated
histone H3 citrullination and ETosis. In addition,
NADPH oxidase/ROS signaling induced by IFN-γ also
facilitates DNA damage and ETosis. IFN-γ-induced ER
stress causes the accumulation of intracellular calcium,
which contributes to PAD4 activation and ETosis. How-
ever, the potential role of IFN-γ-induced mimetic ETosis
in cancer cells remains unclear.
In addition to the direct cytotoxic and growth inhibi-
tory effects of IFN-γ, IFN-γ may facilitate anticancer
immunity through its immunomodulatory actions. In
patients with lung cancer, decreased expression of
granzyme B, perforin, and IFN-γ in infiltrating T cells, NK
cells, and NKT cells can be detected [36]. To regulate the
expression of perforin, granzyme B, CD95, CD95 ligand,
and TRAIL, IFN-γ may increase the mRNA expression
levels of these factors to facilitate cell death in the targeted
cells [4, 15, 67, 78, 80]. Additionally, IFN-γ potentiates
CD95- and TRAIL-induced apoptosis by enhancing
downstream caspase-8 protein expression [43]. IFN-γ
plays an essential role in the induction of cytolytic activity
in CTLs, most likely by affecting the membrane expres-
sion of the interleukin (IL)-2 receptor [29]. Autocrine
IFN-γ stimulation on CD4+ T cells promotes adaptive im-
mune response by augmenting cell survival and cytokine
secretion during T cell activation [61]. IFN-γ is also
secreted from human invariant NKT cells as well as γδ T
cells to promote tumor-associated antigen-specific CTL
responses [37, 54, 69]. For CTL responses, the induction
of MHC class I and transporter associated with antigen
processing (TAP) can be elicited by IFN-γ stimulation in
target cancer cells. Additionally, in activated CTLs, IFN-γ
is effectively produced to promote differentiation and acti-
vation [64]. As a Th1 cytokine, IFN-γ has been shown to
trigger M1-polarized differentiation of anticancer macro-
phage phenotype but not tumor-promoting M2 macro-
phages with immunosuppressive properties [20]. Thus,
IFN-γ plays a key immunomodulatory role in cancer
immunosurveillance.
Cancer immune escape
Cancer cells that survive immunosurveillance by using
so-called immune evasion are crucial for carcinogenesis.
After immunoediting, cancer cells harbor a variety of
strategies to escape immunosurveillance. Basically, the
processes of intrinsically inducing tolerance in cancer
cells themselves and extrinsically inducing resistance to
cytotoxic immune effector cells are initially elicited dur-
ing tumorigenesis [6, 19, 79]. Under immune escape, an
active process that stimulates suppressive factors to
cause inhibitory and/or cytotoxic effects on CTLs, NK
cells, NKT cells, and γδ T cells have been extensively
documented both directly and indirectly.
The intrinsic pathways to escape immunosurveillance
in cancer cells by changing their immunogenicity are
largely used during tumorigenesis. Downregulating
tumor antigen presentation by causing decreased levels
of MHC class I, TAPs, tapasin, and the proteasome sub-
units of latent membrane proteins is common in most
cancers [28, 30, 79]; however, the mechanisms involved
require further investigation. Two of these mechanisms
are abnormal genetic and epigenetic regulation and un-
responsiveness to IFNs, both of which are required for
inducing expression of proteins related to tumor antigen
presentation processes [28]. Activation of oncogenic pro-
cesses such as increased activity of the oncogenes c-Myc
and Bcl-2 and decreased activity of the tumor suppressor
genes p53 and PTEN may strengthen the survival re-
sponses of cells resisting cell death, and the immuno-
logical cytotoxicities from tumor-infiltrating immune
suppressive cells are speculated to be decreased and/or
stopped [33]. Therefore, a combinatorial therapy target-
ing oncogenic signaling pathways in cancer cells can
concomitantly enhance the CTL response [83].
Several extrinsic ways of inducing the production of
humoral factors by tumors and preventing the infiltra-
tion of numerous suppressor cells against effector cyto-
toxic cells are stimulated in the progression of resistance
due to tumorigenesis [3, 7, 21, 22, 50, 79, 82]. By secret-
ing and/or expressing immunosuppressive factors such
as IL-10, transforming growth factor (TGF)-β, prostaglan-
din E2 (PGE2), indoleamine-pyrrole 2,3-dioxygenase
(IDO), galectins, and programmed death ligand 1 (PD-L1),
cancer cells can locally block CTL-mediated cytotoxicity
by causing antigen/MHC loss and T cell dysfunction
[88, 90]. IL-10 is primarily produced by monocytes, M2
cells, Th2 cells, mast cells, Tregs, MDSCs, and MSCs in
response to inflammation, autoimmunity, infection, and
tumorigenesis [40, 55, 62, 75]. Some cancer cells express
more IL-10, which is correlated with cancer progression
from the radial to vertical growth phase as well as with
the development of metastatic competence [38]. Stimula-
tion of IL-10 activates STAT3-mediated suppressors of
cytokine signaling (SOCS) three expression, which confers
anti-inflammatory responses by inhibiting Th1 cell prolif-
eration and altering Th1/Th2 differentiation [23, 93].
PD-L1 (also known as CD274 or B7 homolog 1 (B7-H1))
is abundantly expressed in various human cancers [17] and
can activate PD-1 signaling to induce T cell exhaustion in a
tumor microenvironment [58, 87]. The blockade of tumor-
associated PD-L1, which can increase inactivation and/or
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apoptosis of T cells and result in immune evasion of can-
cers [18], is currently used as a powerful immunotherapy
that acts in a manner similar to targeting immune check-
points such as PD-1 and cytotoxic T-lymphocyte-
associated protein (CTLA) 4 [58, 73, 87].
Tumor microenvironment contains the infiltration of
tumor-promoting immunosuppressive cells such as
TAMs, CD4+CD25+FOXP3+ Tregs, and MDSCs, which
are necessary for tumorigenesis [7, 82]. M2 TAMs,
which display pro-tumoral functions, including the
expression of various growth factors, promotion of
angiogenesis, and suppression of CTL responses, are
commonly present in malignant tumors, which are
linked to a poor prognosis in those patients with breast
cancer, ovarian cancer, some types of glioma, and lymph-
oma [5]. M2 TAMs are therefore targeted for anticancer
therapies [25]. The differentiation of Tregs by IL-10,
IL-35, and TGF-β, all of which are regulated by the ex-
pression and activation of the transcription factor Foxp3,
is crucial for tumorigenesis [14]. Regarding Treg-secreted
IL-10 and TGF-β-suppressed T cell responses, depleting
Tregs or inhibiting their immune inhibitory actions can
enhance anticancer effects [14]. MDSCs abolish the
immune responses during tumor progression [42]. These
cells can inhibit efficient anticancer T cell responses by
inducing Treg activity and M2 differentiation (via IL-10
and TGF-β), depriving amino acid metabolism in T cells
(via arginase 1), releasing cytotoxic oxidizing molecules to
deactivate local T cells (via hydrogen peroxide and peroxy-
nitrite), interfering with T cell migration (CC chemokine
ligand (CCL) two inactivation and disintegrin and metallo-
proteinase domain-containing protein 17-mediated
CD62L cleavage), causing T cell death (via galectin-9), and
inhibiting NK activation (through TGF-β) [16, 26, 42].
Targeting MDSCs is currently implemented as a cancer
immunotherapy.
Cancer cells show hyporesponsiveness to
IFN-γ-dependent immunosurveillance
As described above, cancer cells develop immune evasion
strategies to extrinsically escape from IFN-γ-dependent
immunosurveillance by releasing immunosuppressive
factors as well as recruiting immunosuppressive cells;
however, it has been speculated that the generation of cel-
lular tolerance in cancer cells against IFN-γ-mediated an-
ticancer signaling occurs during tumorigenesis. Basically,
IFN-γ effectively increases MHC class I and cytotoxic pro-
teins related to CTL responses to strengthening the anti-
cancer activity. However, the loss of MHC class I and
cytotoxic priming proteins may result from cellular hypo-
responsiveness to IFN-γ [28]. According to this hypoth-
esis, changes in the activation of IFN-γ signaling should
be considered as an alternative escape pathway from
IFN-γ-dependent immunosurveillance in tumorigenesis.
For controlling IFN-γ signaling, three types of proteins
act as the negative regulator to inhibit IFN-γ: Src
homology 2-containing phosphatase (SHP) 2, the protein
inhibitors of activated STATs, and SOCSs [89]. SOCS1
and SOCS3, which are positively induced by IFN-γ-
activated JAK-STAT pathway, may in turn affect JAK ac-
tivity and STAT recruitment to turn off signaling after
ligand binding [91]. IL-10 is able to induce SOCS3 ex-
pression to block IFN-γ signaling by competing with the
binding of JAK to IFNRGs [39]. Alternatively, the pro-
tein tyrosine phosphatase SHP2 dephosphorylates JAKs
and IFNGR1 to halt the signaling of IFN-γ. Additionally,
STAT1 activation can be directly downregulated by
SHP2 [92]. SHP2 phosphorylation at Tyr542 and Tyr580
on its carboxyl-terminus indicates an activated status of
SHP2 in response to growth factor receptor activation.
Nevertheless, the post-translational modifications of
SHP2 remain unclear. Regarding the negative regulatory
effects of SOCSs and SHP2, it has been speculated that
tumors with SHP2 hyperactivation and SOCS overex-
pression may gain the potential escape mechanisms from
IFN-γ-initiated immune defense responses.
For the development of leukemia, breast cancer, oral
cancer, laryngeal cancer, lung cancer, liver cancer, and gas-
tric cancer, the aberrant expression and activation of
SHP2 has been identified as oncogenic for facilitating
cancer cell hyper-proliferation through a mechanism in-
volving activation of MAPK/extracellular signal-regulated
kinase (ERK) signaling [8, 9, 94]. However, the mecha-
nisms and mutations involved in SHP2 activation remain
unclear. Epidermal growth factor stimulates increased
SHP2 protein tyrosine phosphatase activity to mediate
paxillin dephosphorylation, ERK activation, and cell mi-
gration [13]. Furthermore, the SHP2 inhibitor SPI-112Me
enhances IFN-γ signaling and subsequent related path-
ways including STAT1 activation, IFN-sensitive response
element transactivation, p21 expression, and cell growth
inhibition. Hyporesponsiveness to IFN-γ is speculated to
be accompanied by SHP2 activation.
Helicobacter pylori (H. pylori) is the first identified
carcinogenic bacterium that is a well-known inducer of
gastric tumorigenesis. Upon H. pylori infection of gastric
epithelial cells, the bacteria-secreted virulent factor
CagA binds with SHP2 to cause its direct activation, and
SHP2 is oncogenic for the transformation of gastric epi-
thelial cells [35]. Our recent studies have demonstrated
that CagA-regulated SHP2 activation facilitates IFN-γ
hyporesponsiveness in gastric epithelial cells during H.
pylori infection [85]. For gastric tumorigenesis, SHP2
activation not only induces MAPK/ERK-mediated cell
transformation but also promotes IFN-γ hyporespon-
siveness as an escape from IFN-γ-dependent cancer
immunosurveillance. Interestingly, both human AGS
gastric epithelial adenocarcinoma cells and PC14PE6/
Lin et al. Journal of Biomedical Science  (2017) 24:10 Page 4 of 9
AS2 lung epithelial adenocarcinoma cells show IFN-γ
hyporesponsiveness [12, 48, 76, 77, 81]. There were no
differences in the expression of IFNGR1 and IFNGR2. In
response to IFN-γ-induced STAT1 phosphorylation at
Tyr701, IRF1 transactivation, an increase in STAT1/IRF1
protein levels, CD54 expression, inducible nitric oxide
(NO) synthase (iNOS)/NO induction, cell growth inhib-
ition, and cytotoxicity, both AGS and PC14PE6/AS2
cells are extremely resistant to the hyperactivation of
SHP2. Genetically and pharmacologically inhibiting
SHP2 can reverse IFN-γ signaling and cellular regulation
as described above. These results confirm the negative
role of SHP2 in reducing IFN-γ signaling and illustrate a
possible immune evasive role of SHP2 against IFN-γ-
dependent cancer immunosurveillance. SHP2 may act as
an intracellular factor that induces tolerance and/or sen-
escence in cancer cells in response to IFN-γ stimulation.
For SHP2 regulation in response to IFN-γ treatment,
we have previously demonstrated that either glycogen
synthase kinase (GSK)-3β activation [74] or autophagic
induction [10, 11] facilitates IFN-γ signal transduction
by inhibiting SHP2. In contrast, aberrant oncogenic PI3K
activation as well as a decrease in the expression of the
tumor suppressor PTEN induces AKT activation accom-
panied by GSK-3β inactivation and SHP2 activation. There-
fore, PI3K/PTEN/AKT/GSK-3β/SHP2-facilitated IFN-γ
resistance can be identified in cancer cells [12, 76, 77].
Regarding the notion that oncogenic galectin-3 may
prompt cellular transformation through the activity of Ras
and PI3K/AKT [56, 71], we found that galectin-3 is over-
expressed in AGS cells and is involved in modulating
AKT phosphorylation at Thr308 independent of activation
of either PI3K or 3-phosphoinositide-dependent protein
kinase-1 [76]. Manipulating galectin-3 expression can alter
the signaling of AKT/GSK-3β/SHP2 to affect the cellular
hyporesponsiveness to IFN-γ. According to these findings,
oncogenic signaling pathways related to AKT-mediated
GSK-3β inactivation are speculated to be important for
SHP2 activation as well as IFN-γ hyporesponsiveness. Tar-
geting the possible oncogenic signals in malignancies not
only reduces cell proliferation and cell survival but also
modulates the cellular tolerance of escape from IFN-γ-
dependent cancer immunosurveillance. As reported by
previous studies on a defective response of MHC I expres-
sion in IFN-γ-resistant AGS cells [1, 2], future studies are
needed to determine whether targeting SHP2 can reverse
the lack of immunogenicity in cancer cells and whether
the IFN-γ-induced MHC class I and cytotoxic factors re-
lated to the CTL responses can be overturned.
Implications in cancer immunotherapy
Re-activating tumor-suppressing cells, including NK,
NKT, γδ T cells, and CTLs, is crucial for therapeutic ef-
fects of immune checkpoint blockade. Targeting CTLA4
and PD-1 on CTLs and its principal ligand PD-L1 on
cancer cells is currently used in clinical trials [58, 59].
However, several issues need to be considered for deter-
mining a successful cancer checkpoint immunotherapy
[52]. For the status of T cell activation, biomarkers are
needed to evaluate the efficacy of immune checkpoint
inhibition [52]. For the susceptibility of cancer targeting,
cancer cells may also show immune escape from re-
activated CTL responses following immunotherapy. As
we know, immune checkpoint blocking overcomes T cell
exhaustion and improves CTL responses, including IFN-γ
production and IFN-γ-dependent cancer immunosurveil-
lance [58]. Regarding the role of IFN-γ signaling in cancer
cells in the setting of immune checkpoint remains un-
known, a recent study demonstrated that tumors with
genomic defects or decreases in IFN-γ signaling show
cellular hyporesponsiveness to immune checkpoint
inhibition [27]. Therefore, signaling of IFN-γ may be a
prognostic target as well as a biomarker for a successful
immunotherapy in patients with treatment of immune
checkpoint inhibitors. Furthermore, the therapeutic
combination approaches concurrently by using chemo-
therapy, angiogenic blockers, immune-checkpoint inhibi-
tors, immunostimulatory agents, and cancer vaccines,
which have effectively worked on IFN-γ signaling, are
speculated to be achieved in the near future [59].
Conclusions
As summarized in Fig. 1, after MHC/TCR- and NKG2DL-
mediated pathways, immune surveillance driven by anti-
cancer immune cells (such as NK, NKT, CTL, and γδT
cells) and immune factors (such as IL-2, TNF-α, IFN-γ,
granzyme B, perforin, TRAIL, and CD95L) confers anti-
tumorigenesis. In addition to perforin/granzyme B- and
TRAIL/CD95L-mediated cytotoxicity, IFN-γ/IFN-γ recep-
tor signaling causes the Jak/STAT/IRF1-mediated pathway
to induce anticancer enhancement effects by upregulating
MHC molecules as well as cytotoxic factors. Therefore,
avoiding immune destruction, so called immune escape
from anticancer immune cells and immune factors, is
important for tumor evasion as one of the hallmarks of
cancer. For immune escape, the extrinsic pathways, by
recruiting and activating immunosuppressive tumor-
associated TAMs, Tregs, and MDSCs via IL-10/TGF-β/
PGE2/CCLs/CXC chemokine ligands-regulated mecha-
nisms, are important to defeat immune surveillance.
Immunosuppressive factors such as IDO, arginase, galec-
tins, PGE2, IL-10, and TGF-β are able to inactivate anti-
cancer immune cells. Additionally, the intrinsic pathways
for immune escape can be initiated by immune check-
point co-inhibitory signals such as B7/CTLA4- and
PD-L1/PD-1-mediated immune suppression as well as
by the induction of apoptosis in CTLs through a
CD95L/CD95-mediated pathway.
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By blocking immune checkpoint signaling and deplet-
ing immunosuppressive cells, targeting immune evasion
is now a potent strategy against tumorigenesis. IFN-γ-
facilitated elimination is a key process of elimination in
immunosurveillance; however, there are diverse mecha-
nisms available to cancer cells to escape from IFN-γ-
dependent anticancer signaling. Soluble factors in the
microenvironment and immunosuppressive cells are
speculated to attenuate the IFN-γ response of NK, NKT,
CTL, and γδT cells; it is hypothesized that oncogenic
signals, such as SOCSs and SHP2, in malignancies also
cause cellular hyporesponsiveness, such as immune eva-
sion, in response to IFN-γ anticancer activities, including
cancer cell growth inhibition, cytotoxicity, and MHC
class I expression. Although exogenous IFN-γ treatment
confers limited results in clinical therapy due to its side
effects on systemic inflammation, concurrently reversing
production of IFN-γ in tumor-suppressing cells and sig-
naling of IFN-γ in cancer cells can be utilized to evaluate
the therapeutic efficacy after anticancer treatment, par-
ticularly in immune checkpoint-based therapy.
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